AMICUS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.28 USD | +1.08% |
|
-3.11% | -27.55% |
Presenter SpeechEliana Merle (Analysts)Good afternoon, everyone. I'm Ellie Merle, one of the b...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.
Calendar
2024-05-06
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
10.28
USD
Average target price
18.78
USD
Spread / Average Target
+82.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -27.55% | 3.04B | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.
- Transcript : Amicus Therapeutics, Inc. Presents at UBS Biopharma Conference 2023, Nov-09-2023 01
